Emelia J. Benjamin, MD, ScM, Boston University Chobanian and Avedisian School of Medicine, is the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award. Here she describes what atrial fibrillation is, how the condition announces itself, and why this area of cardiovascular medicine is receiving so much attention.
Emelia J. Benjamin, MD, ScM, is associate provost for faculty development at Boston University Medical Campus; cardiologist at Boston Medical Center, a large urban safety net hospital; professor of medicine, Department of Medicine, at Boston University Chobanian and Avedisian School of Medicine; and professor of epidemiology, Boston University School of Public Health.
At this year’s American Society for Preventive Cardiology’s Congress on CVD Prevention, she delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award—having received the honor for her extraordinary contributions to the field of preventive cardiology.
Here she describes what atrial fibrillation is, how the condition announces itself, and why this area of cardiovascular medicine is receiving so much attention.
Transcript
Can you explain what atrial fibrillation is and discuss how this cardiac condition presents itself?
Atrial fibrillation is an irregularly irregular heart rhythm. People may notice it if they have some kind of fitness device or some kind of heart rate tracking device; they may notice that their heart seems to be skipping or isn't going boom, boom, boom, but rather, ba boom, ba ba ba ba boom, boom, boom, boom like that. Sometimes people even feel it in their chest. On the other hand, oftentimes people are asymptomatic and the concern is that oftentimes their first presentation in the condition is a complication from atrial fibrillation.
Why is the need to focus on atrial fibrillation becoming so much more important at present?
Thank you so much for the question. I personally think that probably part of the problem is ageism, is that for many, many years, the conditions that were most studied happened in younger individuals. Now people are living longer with both cardiovascular disease and many other conditions, and so are going on to develop conditions such as atrial fibrillation. It turns out that the lifetime risk of atrial fibrillation for people of European ancestry is about 1 in 3, for people of African ancestry is about 1 in 5—so it's a very common condition that occurs more and more as people age.
In terms of why is it important now, it's increasing in incidence, meaning the number of new cases; prevalence, the number of existing cases; the lifetime risk; and the complications are significant, including stroke, coronary heart disease, myocardial infarction, heart failure. Turns out there's many other conditions that it’s associated with.
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More